| 3.07 -0.4 (-11.53%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.86 |
1-year : | 4.66 |
| Resists | First : | 3.3 |
Second : | 3.99 |
| Pivot price | 3.25  |
|||
| Supports | First : | 2.2 |
Second : | 1.83 |
| MAs | MA(5) : | 3.41 |
MA(20) : | 3.06 |
| MA(100) : | 2.28 |
MA(250) : | 2.41 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 58.7 |
D(3) : | 65.9 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 3.99 | Low : | 1.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACIU ] has closed above bottom band by 36.9%. Bollinger Bands are 155.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.46 | 3.46 - 3.48 |
| Low: | 3 - 3.02 | 3.02 - 3.04 |
| Close: | 3.03 - 3.07 | 3.07 - 3.1 |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Thu, 09 Oct 2025
Why AC Immune (ACIU) Is Up 15.8% After Promising Early Trial Data for Alzheimer’s Vaccine Candidate - Yahoo Finance
Wed, 08 Oct 2025
AC Immune (ACIU) Is Up 24.2% After Positive ACI-35.030 Trial Publication in Alzheimer's Disease - simplywall.st
Wed, 08 Oct 2025
AC Immune (ACIU) Is Up 24.2% After Positive ACI-35.030 Trial Publication in Alzheimer's Disease - Sahm
Tue, 07 Oct 2025
AC Immune Gears Up For Pipeline Milestones - Will Upcoming Data Catalysts Spark Investor Interest? - RTTNews
Thu, 02 Oct 2025
AC Immune (NASDAQ:ACIU) Trading 3% Higher - Should You Buy? - MarketBeat
Thu, 04 Sep 2025
Biotech AC Immune Extends Cash Runway to 2027 Through Major Restructuring of Neurodegenerative Pipeline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 3.996e+007 (%) |
| Held by Institutions | 38 (%) |
| Shares Short | 1,480 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.867e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -174.7 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 484.5 % |
| Return on Equity (ttm) | -14.7 % |
| Qtrly Rev. Growth | 2.892e+007 % |
| Gross Profit (p.s.) | 58.12 |
| Sales Per Share | -32.9 |
| EBITDA (p.s.) | -2.19936e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.1 |
| Price to Cash Flow | 6.43 |
| Dividend | 0 |
| Forward Dividend | 1.64e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|